KNOLL'S ISOPTIN SR CLEARS FDA WITH FULL NDA; THREE YEARS EXCLUSIVITY FOR DOSAGE AND HYPERTENSIVE INDICATION POSSIBLE; SEARLE'S CALAN-SR ALSO COVERED

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".